There is an increasing use of RNT for patients with extensive bone metastases from castration-resistant prostate cancer, for example with 223Ra or radiolabelled prostate-specific membrane antigen (PSMA) ligands (possibly even subsequently) [39, 40]. This evidence concerns the gene FOLH1 and prostate carcinoma.